Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 6/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.54 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458410 | 0.93 | AGTR2 (0.53) | AGTR2AGTR1GP6 | |
| SCHEMBL4300556 | 0.91 | AGTR2 (0.53) | AGTR2AGTR1GP6 | |
| SCHEMBL4450755 | 0.89 | AGTR2 (0.53) | AGTR2AGTR1GP6 | |
| SCHEMBL4302419 | 0.87 | AGTR2 (0.53) | AGTR2AGTR1GP6 | |
| SCHEMBL4447594 | 0.87 | AGTR2 (0.54) | AGTR2AGTR1GP6 | |
| SCHEMBL4304081 | 0.86 | AGTR2 (0.67) | AGTR2AGTR1 | |
| SCHEMBL9149184 | 0.83 | AGTR2 (0.51) | AGTR2AGTR1GP6 | |
| SCHEMBL1458441 | 0.82 | AGTR1 (0.44) | AGTR2AGTR1GP6 | |
| SCHEMBL1458651 | 0.82 | TLR7 (0.48) | AGTR2AGTR1GP6TLR7 | |
| SCHEMBL1459467 | 0.82 | AGTR1 (0.52) | AGTR2AGTR1GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501798-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258992-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885GP6 1936/4885 |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885GP6 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.